ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (ATLAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01146782
Recruitment Status : Completed
First Posted : June 22, 2010
Results First Posted : June 30, 2014
Last Update Posted : June 30, 2014
Sponsor:
Information provided by (Responsible Party):
ApniCure, Inc.

June 15, 2010
June 22, 2010
January 13, 2014
June 30, 2014
June 30, 2014
June 2010
March 2012   (Final data collection date for primary outcome measure)
Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of >50% and Treated AHI<20 [ Time Frame: first treatment night ]
Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and >30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of >50% and treated AHI<20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.
Not Provided
Complete list of historical versions of study NCT01146782 on ClinicalTrials.gov Archive Site
  • Adverse Event Rate [ Time Frame: 4 weeks ]
    Further categorized as serious and non-serious, device-related and non-device-related, unanticipated and anticipated, and based on level of severity. Adverse events will be evaluated during the trial at the following visits during 28-day take-home period: 7-day, 14-day, 21-day, 28-day follow-up, and any unscheduled visits.
  • Last Treatment Night Response (AHI Reduction) [ Time Frame: At completion of 28 day home use. ]
    Comparing AHI at the last treatment night to the control/baseline night is reported as the percent change in AHI. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and >30/hr = severe OSA. Negative numbers represent a decrease/improvement in AHI, whereas positive numbers represent an increase/no improvement in AHI.
  • Percent Reduction in Oxygen Desaturation Index (ODI) [ Time Frame: First treatment night ]
    Comparing first treatment night to control/baseline night reported as percent change. Negative numbers represent a reduction/improvement in ODI, whereas positive numbers represent increases/no improvement in ODI.
Not Provided
Not Provided
Not Provided
 
Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea
The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)
This is a prospective study of the Attune Sleep Apnea System for the treatment of obstructive sleep apnea. The objective of the study is to demonstrate safety and effectiveness of the Attune Sleep Apnea System to support FDA marketing clearance of the device.
Not Provided
Interventional
Not Applicable
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Obstructive Sleep Apnea
Device: Attune Sleep Apnea System
Console and mouthpiece sleep apnea system
Experimental: Treatment
Treatment with the Attune Sleep Apnea System
Intervention: Device: Attune Sleep Apnea System
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
367
Not Provided
March 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject is between the ages of 18 and 80.
  2. Diagnosis of OSA, based on ODI 10-60 (as assessed per home screening night).
  3. Subject is fluent in English and understands the Study protocol and is willing and able to comply with Study requirements and sign the informed consent form.
  4. BMI < 40.
  5. Subject has a least one molar in each of the four quadrants of the mouth (right upper, right lower, left upper, and left lower).
  6. Subject has proper mouthpiece fit, as assessed by home screening night (See section 8.3).

Exclusion Criteria:

  1. OSA treatment within two weeks prior to Medical/Dental screening visit.
  2. Poor nasal patency as evidenced by Peak Nasal Inspiratory Flow (PNIF) less than 75 l/min (assessed at baseline medical visit). In addition, any ongoing process or condition that limits nasal breathing or indications thereof, including: obligate mouth-breathing, persistent blockage of one or both nostrils resulting in the inability to sleep with the mouth closed, chronic nasal congestion, chronic allergic rhinitis, and intermittent allergic rhinitis that does not respond to non-sedating/non-stimulating medical therapy.
  3. Oral cavity infection or any other oral or dental condition or problem that would limit subject use of the Attune Sleep Apnea System (e.g. dentures, loose tooth/teeth, temporomandibular joint (TMJ) conditions, or any oral or dental condition that the Investigator believes could be exacerbated by the Attune Sleep Apnea System.
  4. Prior use of the Attune Sleep Apnea System.
  5. History of any OSA surgical treatment including uvulopalatopharyngoplasty surgery (UPPP), maxillomandibular advancement surgery (MMA), radio frequency (RF) ablation treatment, palatal stent devices, etc.
  6. Current use or use within the previous 2 weeks of medications or other agents that may affect sleep or PSG, including:

    1. Hypnotics, anxiolytics, anticonvulsants, sedating antihistamines, stimulants, sedating antidepressants or other medications likely to affect neurocognitive function and/or alertness. Patients on stable selective serotonin reuptake inhibitor (SSRI) therapy for > 3 months and who are expected to remain on therapy for the Study duration, may continue SSRI treatment.
    2. Consumption of > 500mg caffeine per day (e.g. > 8 cola-type beverages, > 5 cups of coffee).
    3. Any known illicit drug use or abuse within the past year, or failure to pass drug urine screen test, or alcohol breathalyzer test with result over 0.05% BAL.
    4. Smokers who smoke during the night (interference with PSG).
  7. Any concomitant diagnosed or suspected sleep or chronic neurological disorders, other than OSA, including insomnia, and central sleep apnea.
  8. Currently working nights, rotating night shifts, planned travel across four or more time zones required during Study period, or within two weeks prior to Study enrollment, or sleep schedule not compatible with sleep lab practices.
  9. Potential sleep apnea complications that, in the opinion of the investigator, may affect the health or safety of the participant, including: low blood oxygen, recent near-miss or prior automobile accident due to sleepiness, reported history of severe cardiovascular disease (including NYHA class III or IV heart failure, CAD with angina or MI/stroke in past 6 months, uncontrolled hypertension or hypotension, cardiac arrhythmias), reported respiratory disorders, or use of medication or other treatment which may pose additional risk to the subject or confound the results of the Study.
  10. Female subjects who are pregnant or intend to become pregnant during the study period.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01146782
10753
No
Not Provided
Not Provided
ApniCure, Inc.
ApniCure, Inc.
Not Provided
Principal Investigator: Ian Colrain, PhD Stanford Reasearch Institute (SRI)
ApniCure, Inc.
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP